(SYK) Stryker - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US8636671013
Stock: Surgical Equipment, Implants, Robotics, Neurotechnology, Patient Handling
Total Rating 46
Risk 92
Buy Signal -0.46
| Risk 5d forecast | |
|---|---|
| Volatility | 25.0% |
| Relative Tail Risk | -4.19% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.33 |
| Alpha | -19.70 |
| Character TTM | |
|---|---|
| Beta | 0.664 |
| Beta Downside | 0.619 |
| Drawdowns 3y | |
|---|---|
| Max DD | 16.56% |
| CAGR/Max DD | 0.54 |
EPS (Earnings per Share)
Revenue
Description: SYK Stryker March 04, 2026
Stryker Corporation (SYK) is a medical technology company with two primary segments: MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment provides a range of products including surgical equipment, patient safety technologies, navigation systems, and neurovascular devices. This segment addresses critical needs in operating rooms and intensive care units, a rapidly evolving area in healthcare.
The Orthopaedics segment focuses on implants for joint replacements (hip, knee, shoulder, ankle) and trauma surgeries. This segment also features robotic-assisted surgery platforms, a growing trend in orthopedic procedures aimed at improving precision and patient outcomes. Stryker distributes its products globally to healthcare providers through direct sales and third-party channels.
For more detailed financial analysis and competitive landscaping, ValueRay offers comprehensive insights.
Headlines to watch out for
- Aging global population increases demand for orthopedic and medical devices
- Healthcare capital expenditure trends impact equipment sales
- Regulatory approvals for new medical devices drive market access
- Supply chain disruptions affect manufacturing and product availability
- Reimbursement policies influence hospital purchasing decisions
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 3.25b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 0.84 > 1.0 |
| NWC/Revenue: 27.72% < 20% (prev 32.00%; Δ -4.29% < -1%) |
| CFO/TA 0.11 > 3% & CFO 5.04b > Net Income 3.25b |
| Net Debt (10.85b) to EBITDA (5.58b): 1.94 < 3 |
| Current Ratio: 1.89 > 1.5 & < 3 |
| Outstanding Shares: last quarter (386.5m) vs 12m ago 0.10% < -2% |
| Gross Margin: 63.54% > 18% (prev 0.62%; Δ 6.29k% > 0.5%) |
| Asset Turnover: 55.31% > 50% (prev 52.58%; Δ 2.73% > 0%) |
| Interest Coverage Ratio: 6.45 > 6 (EBITDA TTM 5.58b / Interest Expense TTM 697.0m) |
Altman Z'' 3.86
| A: 0.15 (Total Current Assets 14.76b - Total Current Liabilities 7.79b) / Total Assets 47.84b |
| B: 0.43 (Retained Earnings 20.47b / Total Assets 47.84b) |
| C: 0.10 (EBIT TTM 4.50b / Avg Total Assets 45.41b) |
| D: 0.81 (Book Value of Equity 20.51b / Total Liabilities 25.42b) |
| Altman-Z'' Score: 3.86 = AA |
Beneish M -3.04
| DSRI: 0.91 (Receivables 4.04b/3.99b, Revenue 25.12b/22.59b) |
| GMI: 0.97 (GM 63.54% / 61.52%) |
| AQI: 1.09 (AQ_t 0.61 / AQ_t-1 0.56) |
| SGI: 1.11 (Revenue 25.12b / 22.59b) |
| TATA: -0.04 (NI 3.25b - CFO 5.04b) / TA 47.84b) |
| Beneish M-Score: -3.04 (Cap -4..+1) = AA |
What is the price of SYK shares?
As of March 19, 2026, the stock is trading at USD 349.11 with a total of 2,519,310 shares traded.
Over the past week, the price has changed by +0.01%, over one month by -8.35%, over three months by -1.82% and over the past year by -7.16%.
Over the past week, the price has changed by +0.01%, over one month by -8.35%, over three months by -1.82% and over the past year by -7.16%.
Is SYK a buy, sell or hold?
Stryker has received a consensus analysts rating of 4.06.
Therefore, it is recommended to buy SYK.
- StrongBuy: 13
- Buy: 9
- Hold: 9
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the SYK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 424.9 | 21.7% |
| Analysts Target Price | 424.9 | 21.7% |
SYK Fundamental Data Overview March 18, 2026
P/E Trailing = 41.6639
P/E Forward = 22.4719
P/S = 5.3262
P/B = 5.7484
P/EG = 1.3774
Revenue TTM = 25.12b USD
EBIT TTM = 4.50b USD
EBITDA TTM = 5.58b USD
Long Term Debt = 14.86b USD (from longTermDebt, last quarter)
Short Term Debt = 14.86b USD (from shortTermDebt, last quarter)
Debt = 14.86b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 10.85b USD (from netDebt column, last quarter)
Enterprise Value = 144.62b USD (133.77b + Debt 14.86b - CCE 4.01b)
Interest Coverage Ratio = 6.45 (Ebit TTM 4.50b / Interest Expense TTM 697.0m)
EV/FCF = 33.77x (Enterprise Value 144.62b / FCF TTM 4.28b)
FCF Yield = 2.96% (FCF TTM 4.28b / Enterprise Value 144.62b)
FCF Margin = 17.05% (FCF TTM 4.28b / Revenue TTM 25.12b)
Net Margin = 12.92% (Net Income TTM 3.25b / Revenue TTM 25.12b)
Gross Margin = 63.54% ((Revenue TTM 25.12b - Cost of Revenue TTM 9.16b) / Revenue TTM)
Gross Margin QoQ = 65.22% (prev 63.60%)
Tobins Q-Ratio = 3.02 (Enterprise Value 144.62b / Total Assets 47.84b)
Interest Expense / Debt = 2.56% (Interest Expense 381.0m / Debt 14.86b)
Taxrate = 28.09% (1.27b / 4.51b)
NOPAT = 3.24b (EBIT 4.50b * (1 - 28.09%))
Current Ratio = 1.89 (Total Current Assets 14.76b / Total Current Liabilities 7.79b)
Debt / Equity = 0.66 (Debt 14.86b / totalStockholderEquity, last quarter 22.42b)
Debt / EBITDA = 1.94 (Net Debt 10.85b / EBITDA 5.58b)
Debt / FCF = 2.53 (Net Debt 10.85b / FCF TTM 4.28b)
Total Stockholder Equity = 21.58b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.15% (Net Income 3.25b / Total Assets 47.84b)
RoE = 15.04% (Net Income TTM 3.25b / Total Stockholder Equity 21.58b)
RoCE = 12.35% (EBIT 4.50b / Capital Employed (Equity 21.58b + L.T.Debt 14.86b))
RoIC = 8.51% (NOPAT 3.24b / Invested Capital 38.04b)
WACC = 7.71% (E(133.77b)/V(148.63b) * Re(8.36%) + D(14.86b)/V(148.63b) * Rd(2.56%) * (1-Tc(0.28)))
Discount Rate = 8.36% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.34%
[DCF] Terminal Value 82.21% ; FCFF base≈3.96b ; Y1≈4.89b ; Y5≈8.33b
[DCF] Fair Price = 362.3 (EV 149.49b - Net Debt 10.85b = Equity 138.64b / Shares 382.7m; r=7.71% [WACC]; 5y FCF grow 24.98% → 2.90% )
EPS Correlation: 37.23 | EPS CAGR: 24.42% | SUE: 0.25 | # QB: 0
Revenue Correlation: 92.23 | Revenue CAGR: 14.79% | SUE: 0.97 | # QB: 1
EPS next Quarter (2026-06-30): EPS=3.46 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=26
EPS current Year (2026-12-31): EPS=14.97 | Chg7d=+0.000 | Chg30d=+0.004 | Revisions Net=+11 | Growth EPS=+9.9% | Growth Revenue=+8.7%
EPS next Year (2027-12-31): EPS=16.73 | Chg7d=+0.000 | Chg30d=+0.004 | Revisions Net=+7 | Growth EPS=+11.8% | Growth Revenue=+8.4%
[Analyst] Revisions Ratio: -0.05 (9 Up / 10 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 6.0% (Discount Rate 8.4% - Earnings Yield 2.4%)
[Growth] Growth Spread = +3.1% (Analyst 9.0% - Implied 6.0%)
P/E Forward = 22.4719
P/S = 5.3262
P/B = 5.7484
P/EG = 1.3774
Revenue TTM = 25.12b USD
EBIT TTM = 4.50b USD
EBITDA TTM = 5.58b USD
Long Term Debt = 14.86b USD (from longTermDebt, last quarter)
Short Term Debt = 14.86b USD (from shortTermDebt, last quarter)
Debt = 14.86b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 10.85b USD (from netDebt column, last quarter)
Enterprise Value = 144.62b USD (133.77b + Debt 14.86b - CCE 4.01b)
Interest Coverage Ratio = 6.45 (Ebit TTM 4.50b / Interest Expense TTM 697.0m)
EV/FCF = 33.77x (Enterprise Value 144.62b / FCF TTM 4.28b)
FCF Yield = 2.96% (FCF TTM 4.28b / Enterprise Value 144.62b)
FCF Margin = 17.05% (FCF TTM 4.28b / Revenue TTM 25.12b)
Net Margin = 12.92% (Net Income TTM 3.25b / Revenue TTM 25.12b)
Gross Margin = 63.54% ((Revenue TTM 25.12b - Cost of Revenue TTM 9.16b) / Revenue TTM)
Gross Margin QoQ = 65.22% (prev 63.60%)
Tobins Q-Ratio = 3.02 (Enterprise Value 144.62b / Total Assets 47.84b)
Interest Expense / Debt = 2.56% (Interest Expense 381.0m / Debt 14.86b)
Taxrate = 28.09% (1.27b / 4.51b)
NOPAT = 3.24b (EBIT 4.50b * (1 - 28.09%))
Current Ratio = 1.89 (Total Current Assets 14.76b / Total Current Liabilities 7.79b)
Debt / Equity = 0.66 (Debt 14.86b / totalStockholderEquity, last quarter 22.42b)
Debt / EBITDA = 1.94 (Net Debt 10.85b / EBITDA 5.58b)
Debt / FCF = 2.53 (Net Debt 10.85b / FCF TTM 4.28b)
Total Stockholder Equity = 21.58b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.15% (Net Income 3.25b / Total Assets 47.84b)
RoE = 15.04% (Net Income TTM 3.25b / Total Stockholder Equity 21.58b)
RoCE = 12.35% (EBIT 4.50b / Capital Employed (Equity 21.58b + L.T.Debt 14.86b))
RoIC = 8.51% (NOPAT 3.24b / Invested Capital 38.04b)
WACC = 7.71% (E(133.77b)/V(148.63b) * Re(8.36%) + D(14.86b)/V(148.63b) * Rd(2.56%) * (1-Tc(0.28)))
Discount Rate = 8.36% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.34%
[DCF] Terminal Value 82.21% ; FCFF base≈3.96b ; Y1≈4.89b ; Y5≈8.33b
[DCF] Fair Price = 362.3 (EV 149.49b - Net Debt 10.85b = Equity 138.64b / Shares 382.7m; r=7.71% [WACC]; 5y FCF grow 24.98% → 2.90% )
EPS Correlation: 37.23 | EPS CAGR: 24.42% | SUE: 0.25 | # QB: 0
Revenue Correlation: 92.23 | Revenue CAGR: 14.79% | SUE: 0.97 | # QB: 1
EPS next Quarter (2026-06-30): EPS=3.46 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=26
EPS current Year (2026-12-31): EPS=14.97 | Chg7d=+0.000 | Chg30d=+0.004 | Revisions Net=+11 | Growth EPS=+9.9% | Growth Revenue=+8.7%
EPS next Year (2027-12-31): EPS=16.73 | Chg7d=+0.000 | Chg30d=+0.004 | Revisions Net=+7 | Growth EPS=+11.8% | Growth Revenue=+8.4%
[Analyst] Revisions Ratio: -0.05 (9 Up / 10 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 6.0% (Discount Rate 8.4% - Earnings Yield 2.4%)
[Growth] Growth Spread = +3.1% (Analyst 9.0% - Implied 6.0%)